SecBot SecBot
10-K/A ·Filed Jun 16, 2026

PULM

Pulmatrix, Inc.
NEUTRAL
Impact 2/10
Horizonweeks Processed5mo ago SEC0001493152-26-028902
Amended annual report (potential restatement)
Actionable Insight • Neutral

This amendment is purely administrative with zero material impact. Focus instead on the pending Cullgen merger, which remains subject to CSRC and Nasdaq approvals. Monitor for updates on the End Date extension (now October 12, 2025) and any Asset Sale progress. The company's cash burn rate suggests limited runway for standalone operations if the deal fails.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.50
T+0 close · Jun 16, 2026 · via day close
Latest settled
−6.00%
T+60 · $1.41
Vs SPY
−9.15%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 17 $1.50entry
  2. T+1 · 5mo ago −2.67%α −3.45% · $1.46
  3. T+5 · 5mo ago +2.00%α +3.04% · $1.53
  4. T+20 · 4mo ago +7.33%α +6.02% · $1.61
  5. T+60 · 2mo ago −6.00%α −9.15% · $1.41
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pulmatrix filed an immaterial 10-K/A (Amendment No. 1) solely to correct a typographical error in the date of the Report of Independent Registered Public Accounting Firm included in the original 10-K filing. The financial statements and all other disclosures remain unchanged. The filing also includes updated SOX certifications (Exhibits 31.1 and 32.1). This is a purely administrative correction with no financial or operational impact.

Key Facts

  • Amendment corrects a typographical error in the date of the audit report; no financial restatement or revisions to financial statements.
  • All performance obligations under the Cipla Agreement were satisfied as of December 31, 2025; no revenue recognized in FY 2025 versus $7.8 million in FY 2024.
  • Company generated a net loss of $5.2 million in FY 2025, compared to a net loss of $9.6 million in FY 2024.
  • Cash and cash equivalents totaled $4.1 million as of December 31, 2025, down from $9.5 million a year earlier.
  • The Merger with Cullgen (pre-merger Cullgen stockholders to own ~96.4% of the combined company) is pending CSRC approval; closing conditions include Nasdaq listing approval.
  • Equity incentive plan expired June 10, 2025; no new awards can be granted from it.

Financial Impact

Immaterial, administrative correction only. No changes to any financial statement figures.

none

Risk Factors

  • Merger with Cullgen has not yet received CSRC approval, creating binary outcome risk.
  • Cash balance of $4.1 million provides limited operating runway if the merger is not consummated.
  • Existence of a full valuation allowance against deferred tax assets and $302.3 million accumulated deficit reflects historical losses.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
10-K/A Filing (Primary)0001493152-26-028902
Exhibit: ex32-1.htm0001493152-26-028902
Exhibit: ex31-1.htm0001493152-26-028902
Document: 0001493152-26-028902-index-headers.html0001493152-26-028902
Document: 0001493152-26-028902-index.html0001493152-26-028902
Document: 0001493152-26-028902.txt0001493152-26-028902

Track record

21 reports on PULM

Performance horizon

6 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +15.29% at T+60 after the Aug 7, 2026 report. 6 of 8 went positive at some point.

Filters
  1. Nov 9, 20267d ago 425 Neutral 3/10 Entry $1.36 to $1.33 Now $1.33 −1.85% ▼ −1.84% −0.15% vs SPY
  2. Oct 30, 202617d ago 425 Neutral 3/10 Entry $1.40 to $1.38 Now $1.33 −5.00% ▼ −1.43% +1.27% vs SPY
  3. Oct 23, 202625d ago EFFECT Bearish 5/10 Entry $1.48 to $1.40 Now $1.33 +10.14% ▲ +5.41% +4.85% vs SPY
  4. Oct 22, 202625d ago 425 Neutral 4/10 Entry $1.42 to $1.41 Now $1.33 −6.34% ▼ −0.70% −1.41% vs SPY
  5. Oct 13, 20264w ago 425 Neutral 4/10 Entry $1.38 to $1.43 Now $1.33 −3.62% ▲ +3.62% +4.77% vs SPY
  6. Oct 7, 20265w ago DEFA14A Neutral 2/10 Entry $1.53 to $1.41 Now $1.33 −12.91% ▼ −7.67% −7.39% vs SPY
  7. Oct 2, 20266w ago S-3/A Bearish 5/10 Entry $1.48 to $1.43 Now $1.33 +10.14% ▲ +3.38% +3.80% vs SPY
  8. Sep 28, 20267w ago EFFECT Bearish 5/10 Entry $1.59 to $1.48 Now $1.33 +16.35% ▲ +6.92% +8.12% vs SPY
  9. Sep 25, 20267w ago DEFM14A Bearish 6/10 Entry $1.59 to $1.48 Now $1.33 +16.35% ▲ +6.92% +8.12% vs SPY
  10. Sep 23, 20267w ago S-4/A Neutral 2/10 Entry $1.67 to $1.54 Now $1.33 −20.36% ▼ −7.78% −7.37% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 16, 2026